#United States #Boston #Brenig Therapeutics #BT-267 #BT-409

Brenig Therapeutics Announces Phase 1 Data for BT-267 and BT-409 Updates

Brenig Therapeutics, Inc., a clinical-stage biotechnology firm focused on developing small-molecule therapies for neurological disorders, recently disclosed significant advancements in its clinical trials. This announcement was made during the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026), held from March 17-21, 2026, in Copenhagen, Denmark. The company's Chief Medical Officer, Dr. Tien Dam, is set to present interim data from the ongoing Phase 1 clinical trial for BT-267, a promising brain-penetrant LRRK2 inhibitor, designed to combat Parkinson's disease.

Highlights of BT-267 Presentation

The presentation will underscore essential data regarding the safety, tolerability, and pharmacokinetics (PK) of BT-267. Initial findings indicate a significant central nervous system (CNS) penetration in healthy volunteers—a crucial factor for achieving desired therapeutic effects in neurodegenerative diseases. Dr. Dam remarked, "BT-267 was specifically engineered to deliver robust and sustained inhibition of LRRK2, which is pivotal in the pathophysiology of Parkinson's disease. The preliminary pharmacokinetic data we observe is promising, potentially positioning BT-267 as a best-in-class option within its therapeutic category."

This ongoing phase 1 trial primarily aims to confirm the safety and tolerability profile while further assessing BT-267’s pharmacodynamic properties in a controlled setting. With Parkinson's disease affecting millions worldwide, identifying effective treatments remains critical, and Brenig’s efforts appear to promise a new ray of hope.

Update on BT-409, the NLRP3 Inhibitor

In addition to announcing the progress on BT-267, Brenig Therapeutics revealed that the Phase 1 trial for BT-409, another significant therapeutic target, has commenced with healthy volunteers already dosed. BT-409 is engineered as a brain-penetrant NLRP3 inhibitor that addresses neuroinflammation—a process implicated in various neurological disorders, including Alzheimer’s disease. Early indications show that BT-409 has been well tolerated during initial administration, with no safety concerns reported thus far. As the study proceeds as planned, Brenig remains optimistic about BT-409's potential to emerge as a leading compound in managing neuroinflammatory conditions.

The company’s dedication to bringing innovative treatments to patients reflects its commitment to address the underlying mechanisms of neurodegenerative diseases. Founded in 2021 and supported by a substantial $65 million Series A financing round in mid-2024, Brenig Therapeutics continues to build its reputation in the biotech sector through strategic advancements in drug development.

The Research Landscape Ahead

The details surrounding BT-267 and BT-409 exemplify Brenig Therapeutics' strategic initiative to explore novel small-molecule therapies designed to tackle fundamental neurological challenges. As resources converge on clinical trials, future updates are highly anticipated by investors and the medical community alike. Brenig acknowledges that while the scientific path can be fraught with challenges, its innovative approach continues to propel the company forward in the field of neuroscience.

In anticipation of further developments, Brenig Therapeutics remains committed to transparency and collaboration as it navigates the exciting yet challenging landscape of neuropharmaceutical research.

As they prepare for the AD/PD 2026 conference presentation, both the company and the broader neurological research community are eager to witness the evolution of BT-267 and BT-409 in the quest for groundbreaking treatments against neurodegenerative conditions.